秋水仙碱治疗急性和慢性冠脉综合征
本文综述秋水仙碱在急性和慢性冠脉综合征中的药理机制与临床证据。秋水仙碱通过抑制NLRP3炎症小体及微管聚合,减少IL-1β和IL-18生成,长期使用与心血管事件率降低相关且安全性良好,可能成为治疗急慢性冠脉综合征的新型安全廉价药物。
要点
- 秋水仙碱通过抑制NLRP3炎症小体和微管聚合发挥独特抗炎作用。
- 长期使用秋水仙碱与急性和慢性冠脉综合征心血管事件率降低相关。
- 秋水仙碱总体安全性良好,可能成为安全廉价的新治疗选择。
核心结论
- 基于现有文献,秋水仙碱正成为治疗急性和慢性冠脉综合征的可能新型、安全且廉价的药物。
研究设计与样本
- 本文为综述,回顾秋水仙碱对冠状动脉疾病病理生理的影响、基本药理学及最重要和最新的临床研究。
主要发现
- 秋水仙碱可集中于白细胞尤其是中性粒细胞,阻断微管蛋白聚合,影响微管组装。
- 秋水仙碱抑制NLRP3炎症小体,减少IL-1β和IL-18的产生。
- 长期使用秋水仙碱与慢性和急性冠脉综合征中心血管事件率降低相关,总体安全性良好。
临床怎么用
- 在现有文献基础上,秋水仙碱可作为急性和慢性冠脉综合征的可能治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Colchicine is an ancient drug, traditionally used for the treatment and prevention of gouty attacks; it has become standard of treatment for pericarditis with a potential role in the treatment of coronary artery disease. Atherosclerotic plaque formation, progression, destabilisation and rupture are influenced by active proinflammatory cytokines interleukin (IL)-1β and IL-18 that are generated in the active forms by inflammasomes, which are cytosolic multiprotein oligomers of the innate immune system responsible for the activation of inflammatory responses. Colchicine has a unique anti-inflammatory mechanism: it is not only able to concentrate in leucocytes, especially neutrophils, and block tubulin polymerisation, affecting the microtubules assembly, but also inhibits (NOD)-like receptor protein 3 (NLRP3) inflammasome. On this basis, colchicine interferes with several functions of leucocytes and the assembly and activation of the inflammasome as well, reducing the production of interleukin 1β and interleukin 18. Long-term use of colchicine has been associated with a reduced rate of cardiovascular events both in chronic and acute coronary syndromes, with an overall good safety profile. This review will focus on the influence of colchicine on the pathophysiology of coronary artery disease, reviewing essential pharmacology and discussing the most important and recent clinical studies. On the basis of current literature, colchicine is emerging as a possible new valuable, safe and cheap agent for the treatment of acute and chronic coronary syndromes.
引用
- Imazio M, Andreis A, Brucato A, et al. Colchicine for acute and chronic coronary syndromes. Heart. 2020. PMID: 32611559. doi:10.1136/heartjnl-2020-317108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。